Genetic and nongenetic factors in assessing the prognosis of patients after myocardial infarction with high medical adherence
Open Access
- 17 July 2021
- journal article
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 20 (4), 2773
- https://doi.org/10.15829/1728-8800-2021-2773
Abstract
Aim. During one-year follow-up, to assess the effect of genetic and nongenetic factors on the risk of poor outcomes in patients after myocardial infarction (MI) with high medical adherence. Material and methods. The study included 250 patients admitted to the hospital due to MI in the period from September 1, 2018 to May 1, 2019 and with a potentially high medical adherence. Twelve months after MI, patients were assessed for adherence to therapy and the effect of genetic and nongenetic factors on the patient prognosis. Results. Within 12 months after MI, 70 (28,0%) patients had a composite endpoint: all-cause death, MI, cerebral stroke, and nonelective coronary revascularization. There were following factors increasing the risk of composite endpoint: non-Q-wave MI (relative risk (RR), 2,63; 95% confidence interval (CI): 1,63-4,25 (p=0,001); left ventricular ejection fraction ≤35% — RR, 2,03; 95% CI: 1,17-3,50 (p<0,0001); CYP2C19 GA/AA genotype (RR, 1,58; 95% CI: 1,06-2,37 (p<0,00001)). Conclusion. The study results allow identifying patients with a high risk of poor outcome: patients with non-Q-wave MI, left ventricular ejection fraction ≤35%, and CYP2C19 GA/AA genotype.Keywords
This publication has 19 references indexed in Scilit:
- Adherence to the treatment of patients in the long-term supervision period after myocardial infarction (according to the REGATA register)Kardiologiia, 2020
- COMPLIANCE AND WAYS OF ITS IMPROVEMENT IN PATIENTS AFTER TRANSCUTANEOUS CORONARY INTERVENTION IN ACUTE CORONARY SYNDROME WITHOUT ELEVATION OF ST SEGMENTNauka Molodykh (Eruditio Juvenium), 2020
- Pharmacogenetic Approaches to Enhancing Efficacy and Safety of Statins as Illustrated by the Example of AtorvastatinSafety and Risk of Pharmacotherapy, 2020
- The role of treatment adherence after myocardial infarction (according to the acute myocardial infarction registry)Complex Issues of Cardiovascular Diseases, 2019
- The bisoprolol efficiency predictors in patients with stable angina after myocardial infarctionMedical Council, 2019
- PHARMACOGENETIC FEATURES OF THERAPY OF PATIENTS WITH ATHEROSCLEROSISThe Russian Archives of Internal Medicine, 2018
- The first russian expert consensus on the quantitative evaluation of the treatment adherence: pivotal issues, algorithms and recommendationsMedical news of the North Caucasus, 2018
- MORTALITY FROM MYOCARDIAL INFARCTION IN RUSSIA IN THE YEARS 2006 AND 2015Russian Journal of Cardiology, 2017
- Features of healthy-preserving behavior and adherence to treatment by doctors at different stages of professional developmentI.P. Pavlov Russian Medical Biological Herald, 2015
- Practical recommendations for pharmacogenomics-based prescription: 2010 ESF–UB Conference on Pharmacogenetics and PharmacogenomicsPharmacogenomics, 2011